Sitemap > Breaking Research > Infectious Diseases
Displaying 201 - 250 of 4290 results
- Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: findings from linked SEER-Medicare data.
- Dexamethasone inhibits the HSV-tk/ ganciclovir bystander effect in malignant glioma cells.
- Differential response of TIMP-3 null mice to the lung insults of sepsis, mechanical ventilation, and hyperoxia.
- An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
- Effects of non-steroidal anti-inflammatory drugs on the pharmacokinetics and elimination of aciclovir in rats.
- The effect of treatment with a protease inhibitor on mycobacterial infection.
- Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties.
- Improved synthesis of daunomycin conjugates with triplex-forming oligonucleotides. The polypurine tract of HIV-1 as a target.
- Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives.
- Neutralization of endotoxin by a phospholipid emulsion in healthy volunteers.
- Vav proteins are required for B-lymphocyte responses to LPS.
- Ipr1 gene mediates innate immunity to tuberculosis.
- Long-term consequences of treatment interruptions in chronically HIV-1-infected patients.
- Oral silymarin for chronic hepatitis C - a retrospective analysis comparing three dose regimens.
- Randomized, investigator-blinded, multicenter study of gatifloxacin versus amoxicillin/clavulanate treatment of recurrent and nonresponsive otitis media in children.
- Compartmentalization of HIV-1 in the central nervous system: role of the choroid plexus.
- Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
- An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins.
- Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus.
- Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.
- Mortality risk factors with nosocomial Staphylococcus aureus infections in intensive care units: results from the German Nosocomial Infection Surveillance System (KISS).
- An antibody specific for the C-terminal tail of the gp41 transmembrane protein of human immunodeficiency virus type 1 mediates post-attachment neutralization, probably through inhibition of virus-cell fusion.
- Design, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration.
- Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide.
- A novel small animal model for HIV-1 infection.
- Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase.
- Discovery and optimisation of potent, selective, ethanolamine inhibitors of bacterial phenylalanyl tRNA synthetase.
- Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
- The IkappaB kinase is a key factor in triggering influenza A virus-induced inflammatory cytokine production in airway epithelial cells.
- Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection.
- Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.
- Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C.
- The adipocyte as an important target cell for Trypanosoma cruzi infection.
- Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation.
- Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety.
- Antiviral activity of ovotransferrin derived peptides.
- Outer membrane protein P6 of nontypeable Haemophilus influenzae is a potent and selective inducer of human macrophage proinflammatory cytokines.
- Role of interleukin-6 in mortality from and physiologic response to sepsis.
- Interleukin-15 enhances innate and adaptive immune responses to blood-stage malaria infection in mice.
- Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa.
- Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway.
- Synthesis and biological evaluation of N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid as a potential inhibitor of GAR Tfase and the de novo purine biosynthetic pathway.
- Aptamers directed to HIV-1 reverse transcriptase display greater efficacy over small hairpin RNAs targeted to viral RNA in blocking HIV-1 replication.
- mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer.
- Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105.
- The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.
- Neuroprotective and anti-human immunodeficiency virus activity of minocycline.
- Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation.
- Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.
- Immunomodulatory activities of small host defense peptides.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 Next >